Mergers & Acquisitions
Jul. 3, 2010
Abraxis Sale Could Yield Big Payout
Attorneys are working on a structure for the $2.9 billion-plus sale of Los Angeles-based Abraxis BioScience Inc. that's normally reserved for privately held companies.
Daily Journal Staff Writer
Attorneys are working on a structure for the $2.9 billion sale of Abraxis BioScience Inc. that's normally reserved for privately held companies and could net shareholders an additional $650 million.
Abraxis stockholders, including the company's founder and majority shareholder, will be entitled to additional payouts as future milestones for the biotechnology firm's cancer ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In